Clinical Benefit of Tafamidis 61mg for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Patients in Korean Population in the Real-world Setting, Multicenter, Non-interventional Study
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The purpose of this clinical trial is to learn about the effects of the study medicine (called Tafamidis 61milligrams (mg)) for the potential treatment of Transthyretin amyloid cardiomyopathy (ATTR-CM). This study is seeking participants who were prescribed Tafamidis 61mg after being diagnosed with ATTR-CM and have taken Tafamidis 61mg at least once. We will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe and effective.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:
• Age ≥19 years
• Patients diagnosed with ATTR-CM (ATTRwt and ATTRv) with tissue biopsy or nuclear scintigraphy
• Patients who was prescribed Tafamidis 61mg after being diagnosed with ATTR-CM and have taken Tafamidis 61mg at least once.
Locations
Other Locations
Republic of Korea
Pusan National University Hospital
ACTIVE_NOT_RECRUITING
Busan
Gangnam Severance Hospital
RECRUITING
Seoul
Severance Hopital, Yonsei University Health System
ACTIVE_NOT_RECRUITING
Seoul
Contact Information
Primary
Pfizer CT.gov Call Center
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Time Frame
Start Date: 2024-03-19
Estimated Completion Date: 2026-04-30
Participants
Target number of participants: 13
Treatments
ATTR-CM patients in Korea
transthyretin amyloid cardiomyopathy (ATTR-CM) patients in Korea
Related Therapeutic Areas
Sponsors
Leads: Pfizer